TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3266255

Group type: EXPERIMENTAL
Intervention: Social influences model program taught by peer leaders and teachers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health consequences program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing-curriculum condition
Number of subjects: 0
Study: 28643427

Group type: EXPERIMENTAL
Intervention: PVR after uroflowmetry
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: PVR after uroflowmetry and random PVR divided into three groups
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: PVR after uroflowmetry in patients with bladder capacity >400 mL
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Random PVR in patients with bladder capacity >400 mL
Number of subjects: 77
Study: 27378812

Group type: EXPERIMENTAL
Intervention: Particle-separated environment (PSE)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Conventional environment (CE)
Number of subjects: 11
Study: 25032805

Group type: EXPERIMENTAL
Intervention: Heart rate group <70 beats per minute
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Heart rate group 70-79 beats per minute
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Heart rate group 80-89 beats per minute
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Heart rate group ≥90 beats per minute
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Normal weight subjects
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Overweight subjects
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Obese subjects
Number of subjects: 160
Study: 24066743

Group type: EXPERIMENTAL
Intervention: CMX001 (100 mg twice weekly)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: CMX001 (200 mg weekly or higher)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: CMX001 (200 mg twice weekly)
Number of subjects: 230
Study: 19773749

Group type: EXPERIMENTAL
Intervention: Flushknife (endo-knife with water-jet function)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Flexknife (electrosurgical endo-knife without water-jet function)
Number of subjects: 49
Study: 17394563

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin (850 mg twice daily)
Number of subjects: 0
Study: 16635226

Group type: EXPERIMENTAL
Intervention: Motilin (300 ng/kg/30 min i.v.)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Atropine (12 microg/kg/h) with motilin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Atropine alone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Motilin infusion
Number of subjects: 21
Study: 12705362

Group type: EXPERIMENTAL
Intervention: L-thyroxine 8-10 microg/kg/day in newborns
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: L-thyroxine 15 microg/kg/day in infants
Number of subjects: 34

Group type: COMPARATOR
Intervention: Untreated hyperthyroid adults
Number of subjects: 34

Group type: COMPARATOR
Intervention: Controls (not specified)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Hypothyroid newborns at diagnosis
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Hypothyroid infants at diagnosis
Number of subjects: 34
Study: 10626716

Group type: EXPERIMENTAL
Intervention: Active TENS unit
Number of subjects: 40

Group type: COMPARATOR
Intervention: Inactive TENS unit
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (TENS on and TENS off)
Number of subjects: 40
Study: 9174876

Group type: EXPERIMENTAL
Intervention: Aerosolized heparin inhalation (1,000 U/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 1605988

Group type: EXPERIMENTAL
Intervention: Biofeedback and pelvic floor exercises
Number of subjects: 135

Group type: COMPARATOR
Intervention: Mixed incontinence (MI) group
Number of subjects: 135
Study: 3522407

Group type: EXPERIMENTAL
Intervention: Tinidazole (single oral 2 g dose)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 29758184

Group type: EXPERIMENTAL
Intervention: Oral voriconazole
Number of subjects: 194

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 194
Study: 27197020

Group type: EXPERIMENTAL
Intervention: Single screw-rod anterior instrumentation (SSRAI)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Double screw-rod anterior instrumentation (DSRAI)
Number of subjects: 51
Study: 25111123

Group type: COMPARATOR
Intervention: Glucose beverage
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fructose beverage
Number of subjects: 24
Study: 23894797

Group type: EXPERIMENTAL
Intervention: Mortality Salience (MS)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Non-Mortality Salience (non-MS)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Rational conceptual mode
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Experiential conceptual mode
Number of subjects: 62
Study: 19815369

Group type: EXPERIMENTAL
Intervention: Education program for patients receiving VKAs, including individual sessions, telephone support, group sessions, and educational tools.
Number of subjects: 0
Study: 17515687

Group type: EXPERIMENTAL
Intervention: Active Recovery (AR)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Passive Recovery (PR)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Stretching (ST)
Number of subjects: 10
Study: 15347426

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention tailored to improve pharmacological management of hypertension and hypercholesterolaemia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 11229858

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metamizol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antipyretic treatment
Number of subjects: 0
Study: 9653015

Group type: COMPARATOR
Intervention: HLA-DRB1*0701
Number of subjects: 39

Group type: COMPARATOR
Intervention: HLA-DQB1*0201
Number of subjects: 39

Group type: COMPARATOR
Intervention: HLA-DPB1*1601
Number of subjects: 39
Study: 8281625

Group type: EXPERIMENTAL
Intervention: Droloxifene 20 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Droloxifene 40 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Droloxifene 100 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Droloxifene 200 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Droloxifene 300 mg
Number of subjects: 30
Study: 2912024

Group type: EXPERIMENTAL
Intervention: vindesine 3 mg/m2 weekly
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: spirogermanium 80 mg/m2 three times weekly (escalated to 120 mg/m2)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: spirogermanium
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: vindesine
Number of subjects: 54
Study: 1155056

Group type: EXPERIMENTAL
Intervention: Ampicillin plus nasal decongestant
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Ampicillin plus irrigation
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Cephradine plus nasal decongestant
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Cephradine plus irrigation
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Erythromycinestolate plus nasal decongestant
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Erythromycinestolate plus irrigation
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 300
Study: 30367891

Group type: EXPERIMENTAL
Intervention: Raisins near (20 cm), M&Ms far (70 cm)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Both foods near
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: M&Ms near, raisins far
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Both far
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: M&Ms near
Number of subjects: 248
Study: 28768173

Group type: EXPERIMENTAL
Intervention: NNC0090-2746 (1.8 mg subcutaneously once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg subcutaneously once daily)
Number of subjects: 0
Study: 25358038

Group type: EXPERIMENTAL
Intervention: High-similarity character with severe depression
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Low-similarity character with severe depression
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no article)
Number of subjects: 80
Study: 24254035

Group type: EXPERIMENTAL
Intervention: Acupressure (12 sessions, 3 times/week for 1 month, using TENS acupuncture pen at ST-36, GB-34, SP-6, K-1 points)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (no acupressure treatment)
Number of subjects: 118
Study: 21300382

Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 115
Study: 19997797

Group type: EXPERIMENTAL
Intervention: Intravenous administration of cefmetazol on the day of surgery (group 1)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Intravenous administration of cefotiam for 3 days (group 2)
Number of subjects: 275
Study: 22524979

Group type: EXPERIMENTAL
Intervention: IV acetaminophen (OFIRMEV(®); 1,000 mg, 15 minute infusion)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: PO acetaminophen (2 Tylenol(®) 500 mg caplets)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: PR acetaminophen (2 Feverall(®) 650 mg suppositories)
Number of subjects: 6
Study: 17356929

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone (4 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (macular focal and grid laser photocoagulation)
Number of subjects: 16
Study: 12842371

Group type: EXPERIMENTAL
Intervention: DTP-IPV or IPV after HTMV
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Standard measles vaccine (control)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: HTMV without additional DTP-IPV or IPV
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: DTP-IPV after routine HTMV
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: No DTP-IPV after routine HTMV
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: DTP or IPV after HTMV (combined results)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: No DTP or IPV after HTMV (combined results)
Number of subjects: 2000
Study: 10471182

Group type: EXPERIMENTAL
Intervention: Vaxigrip injection
Number of subjects: 1356
Study: 7794571

Group type: EXPERIMENTAL
Intervention: cilazapril
Number of subjects: 17

Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 17
Study: 2190758

Group type: EXPERIMENTAL
Intervention: Hydrocolloid dermatologic patch (Actiderm) plus topical beta‐methasone valerate 0.1 percent cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical beta‐methasone valerate 0.1 percent cream alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrocolloid dermatologic patch (Actiderm) alone
Number of subjects: 0
Study: 380386

Group type: EXPERIMENTAL
Intervention: Combined electrostimulation-hypalgesia with nitrous-oxide oxygen mixture
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nitrous-oxide and oxygen mixture only (Control)
Number of subjects: 30
Study: 31955942

Group type: EXPERIMENTAL
Intervention: Smartphone app-based self-management program
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (one call a month from research staff)
Number of subjects: 44
Study: 29143122

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (3200 IU/day for 5 weeks)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo with normal concentration of vitamin D (SUF)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo group with vitamin D deficiency (DEF)
Number of subjects: 3
Study: 27265887

Group type: EXPERIMENTAL
Intervention: Epilepsy nurse (EN) group
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 187
Study: 27252754

Group type: EXPERIMENTAL
Intervention: Fifth generation bonding agent
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Seventh generation bonding agent
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sealant alone
Number of subjects: 64
Study: 23945138

Group type: EXPERIMENTAL
Intervention: WalkLink+: prompted and provided feedback on participants' online and in‐person social‐network interactions to expand networks for PA, plus provided evidence‐based online walking program and weekly walking tips
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: WalkLink: evidence‐based online walking program and weekly tips only
Number of subjects: 308

Group type: COMPARATOR
Intervention: Minimal Treatment Control: weekly tips only
Number of subjects: 308
Study: 20584793

Group type: EXPERIMENTAL
Intervention: Injection plus exercise
Number of subjects: 232

Group type: COMPARATOR
Intervention: Exercise only
Number of subjects: 232
Study: 18622144

Group type: EXPERIMENTAL
Intervention: F13B His95Arg variant in patients with LVD
Number of subjects: 887

Group type: COMPARATOR
Intervention: None of the 21 other prothrombotic gene variants
Number of subjects: 887
Study: 16860068

Group type: EXPERIMENTAL
Intervention: Methylene blue directed biopsies (MBDB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Random 4 quadrant biopsies (RB)
Number of subjects: 30
Study: 12816306

Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Epithelial free gingival graft (EFGG)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Connective tissue graft (CTG)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Guided tissue regeneration (GTR)
Number of subjects: 91
Study: 10971105

Group type: EXPERIMENTAL
Intervention: 0.5 IU/kg per week subcutaneous recombinant human GH
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: 1.0 IU/kg per week subcutaneous recombinant human GH
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Both doses of GH
Number of subjects: 145
Study: 8569467

Group type: EXPERIMENTAL
Intervention: Prednisone (CS) + oral cyclophosphamide (CYC) + plasma exchanges (PE)
Number of subjects: 342

Group type: COMPARATOR
Intervention: CS + PE
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: CS + oral CY
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: CS + pulse CY + PE
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Five-factors score (FFS)
Number of subjects: 342
Study: 1379376

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 5

Group type: COMPARATOR
Intervention: rhEpo
Number of subjects: 5
Study: 6352967

Group type: EXPERIMENTAL
Intervention: Self-care instructions and health education program provided to families (intervention group)
Number of subjects: 433

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 433
Study: 31952938

Group type: EXPERIMENTAL
Intervention: Probiotics (5 × 10^9 cfu/capsule)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 29894491

Group type: EXPERIMENTAL
Intervention: Basic Life Support (BLS) attempts initiation
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Willingness to perform CPR
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Willingness to use an AED device
Number of subjects: 501

Group type: COMPARATOR
Intervention: Willingness to initiate BLS attempts by gender
Number of subjects: 501

Group type: COMPARATOR
Intervention: Willingness to use an AED device by gender
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Knowledge and willingness for BLS attempts by age
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Knowledge and willingness for AED use by age
Number of subjects: 501
Study: 27214145

Group type: EXPERIMENTAL
Intervention: Inhaled, nebulized AZD5423 at doses of at least 300 μg for 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled, nebulized AZD5423
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other biomarkers tested (osteocalcin, TRAP5b, DHEA-S, 4β-OH-cholesterol)
Number of subjects: 0
Study: 24862742

Group type: COMPARATOR
Intervention: 40 mg of oral MPH
Number of subjects: 54
Study: 23210418

Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride test dentifrice
Number of subjects: 150

Group type: COMPARATOR
Intervention: 0.30% triclosan/copolymer dentifrice
Number of subjects: 150
Study: 20623459

Group type: EXPERIMENTAL
Intervention: Structured Interview of Personality Organization (STIPO) scales
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Clinical severity indicators (axis‐II comorbidity, suicide attempts, self‐destructive behaviour, service utilization)
Number of subjects: 104
Study: 19002270

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (n=24)
Number of subjects: 47
Study: 15852173

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS)
Number of subjects: 56

Group type: COMPARATOR
Intervention: CT-scan
Number of subjects: 56

Group type: COMPARATOR
Intervention: b-mode and colour-duplex imaging
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: CEUS
Number of subjects: 56
Study: 12823852

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 49
Study: 11990437

Group type: EXPERIMENTAL
Intervention: CO2 laser in continuous mode with a focused beam of 0.8 mm (Group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CO2 laser in pulsed mode with defocused beam of 4 mm (Group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated controls (Group C)
Number of subjects: 30
Study: 10658377

Group type: EXPERIMENTAL
Intervention: Optimal protamine dose determined for residual heparin concentration (P group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Initial fixed dose of protamine, 1.67 mg protamine per milligram total heparin (C group)
Number of subjects: 20
Study: 8557059

Group type: EXPERIMENTAL
Intervention: Urodilatin (20, 40, or 60 ng kg‐1 min‐1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Urodilatin (40 ng kg‐1 min‐1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Urodilatin (60 ng kg‐1 min‐1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Urodilatin (40 or 60 ng kg‐1 min‐1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 1.25 mg salbutamol
Number of subjects: 18
Study: 2095163

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Potassium chloride
Number of subjects: 264

Group type: COMPARATOR
Intervention: 10% glucose solution
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo (200 ml of 2% glucose solution)
Number of subjects: 264
Study: 6985882

Group type: EXPERIMENTAL
Intervention: 600 mg/day of UDCA
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 150 mg/day of UDCA
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 72
Study: 31899739

Group type: EXPERIMENTAL
Intervention: Osteoblastic cell therapy
Number of subjects: 67

Group type: COMPARATOR
Intervention: BMAC treatment
Number of subjects: 67
Study: 31158840

Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl 20 mg
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl 80 mg
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 179
Study: 28148682

Group type: EXPERIMENTAL
Intervention: High-protein diet (25% of energy)
Number of subjects: 811

Group type: COMPARATOR
Intervention: Low-protein diet (15% of energy)
Number of subjects: 811
Study: 25816354

Group type: EXPERIMENTAL
Intervention: SQ-LNS without zinc, placebo tablet
Number of subjects: 2435

Group type: EXPERIMENTAL
Intervention: SQ-LNS containing 5mg zinc, placebo tablet
Number of subjects: 2435

Group type: EXPERIMENTAL
Intervention: SQ-LNS containing 10mg zinc, placebo tablet
Number of subjects: 2435

Group type: EXPERIMENTAL
Intervention: SQ-LNS without zinc and 5mg zinc tablet
Number of subjects: 2435

Group type: COMPARATOR
Intervention: Control (NIC)
Number of subjects: 2435

Group type: EXPERIMENTAL
Intervention: SQ-LNS (IC)
Number of subjects: 2435
Study: 23725208

Group type: EXPERIMENTAL
Intervention: Emotion recognition training
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control procedures
Number of subjects: 190
Study: 21415814

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring on two occasions, 7-15 days apart, on a stable antihypertensive regimen.
Number of subjects: 25
Study: 19102810

Group type: EXPERIMENTAL
Intervention: FFQ for assessment of dietary EPA and DHA
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Oily fish intake
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Total fish intake
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Marine food products intake
Number of subjects: 65
Study: 17890725

Group type: EXPERIMENTAL
Intervention: Lipiodol flushing
Number of subjects: 158
Study: 15351581

Group type: COMPARATOR
Intervention: HT soy grits
Number of subjects: 29
Study: 11569761

Group type: EXPERIMENTAL
Intervention: Optimism regarding gains
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimism regarding losses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low optimism
Number of subjects: 0
Study: 9149554

Group type: EXPERIMENTAL
Intervention: 15 wrist flexion, 15 N resistance, 6 motions/min
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 15 wrist flexion, 45 N resistance, 12 motions/min
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 45 degrees wrist flexion, 45 N resistance, 15 motions/min
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 7
Study: 8182996

Group type: EXPERIMENTAL
Intervention: Prophylaxis with antacids and H2 blockers (AA+H2)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Prophylaxis with sucralfate
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study: 3241118

Group type: EXPERIMENTAL
Intervention: Keyboard
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Light Pen
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Voice Recognition
Number of subjects: 20